Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect.
- Author:
Amir Hassan ZARNANI
1
;
Monireh TORABI-RAHVAR
;
Mahmood BOZORGMEHR
;
Mehri ZAREIE
;
Nazanin MOJTABAVI
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Neoplasms; Dendritic cells; Vaccination; Helper protein; Immunotherapy
- MeSH: Animals; Blotting, Western; Colonic Neoplasms*; Dendritic Cells; Fluorescent Antibody Technique; Immunotherapy; Mice; Ovalbumin; Ovum; Survival Rate; Tumor Burden; Vaccination
- From:Cancer Research and Treatment 2015;47(3):518-526
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Targeted immunotherapy using dendritic cells (DCs) has been employed in numerous investigations aiming at combating neoplasms. We previously showed that copulsing of an antigen with a helper protein could considerably enhance antigen presenting capacity of ex vivo-generated DCs. In this study, we attempted to administer an effective treatment in a murine model of colon cancer with DCs pulsed with the mixture of a tumor-specific gp70-derived peptide (AH1) and a helper protein, ovalbumin (OVA). MATERIALS AND METHODS: First, the presence of gp70 in CT26 tumor cells and tumor tissues was verified using immunofluorescence and Western blot analyses. Next, DCs were purified from normal mice, loaded ex vivowith AH1 and OVA (DC-Pep-OVA), and injected into tumor-bearing mice. Tumor volume, in vitro antigen (Ag)-specific proliferation of splenic cells, and survival rate were measured to determine the efficacy of DC-Pep-OVA. As the control groups, tumor-bearing mice were vaccinated with DC-Pep, unpulsed DC, and DCs loaded with a mixture of OVA and an irrelevant peptide (P15), or were not vaccinated at all. RESULTS: DC-Pep-OVA showed superior efficacy over other groups, as indicated by smaller tumor volume, higher Ag-specific proliferation rate of splenic cells, and prolonged survival. CONCLUSION: Overall, in the present study we showed for the first time that DCs copulsed with AH1 (tumor Ag) and OVA (helper molecule) could be considered as potentially robust weapons for use in future antitumor immunotherapies.
